GENE ONLINE|News &
BeiGene’s Brukinsa Bags Second FDA Approval, to Rival Imbruvica in Treating a Rare Cancer
On September 1st, BeiGene announced that the FDA has greenlit its Brukinsa (zanubrutinib), a small molecule inhibitor of Bruton’s tyrosine kinase (BTK) for treating adult patients with a rare type of lymphoma called Waldenström’s macroglobulinemia (WM).
This is Brukinsa's second FDA approval, after bagging authorization from the agency for treating Mantle Cell Lymphoma in 2019. Besides the US, the drug has received marketing approval in five countries for this indication. Before the latest FDA approval, Brukinsa was approved for treating WM in China and Canada.
This is Brukinsa's second FDA approval, after bagging authorization from the agency for treating Mantle Cell Lymphoma in 2019. Besides the US, the drug has received marketing approval in five countries for this indication. Before the latest FDA approval, Brukinsa was approved for treating WM in China and Canada.
GO Prime with only $1.49 now
LATEST
Lupin Secures US FDA Tentative Approval for Oxcarbazepine ER Tablets Manufactured in Nagpur
2025-06-18
Global Pharmaceutical Sector Records $6.96 Billion in May 2025 Deal Activity with Three Major Agreements Driving 59 Percent of M&A Value
2025-06-18
New Device Promises to Streamline CAR T-Cell Therapy Production for Earlier Cancer Treatment
2025-06-18
